Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
LGND
LGND
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
LGND News
S&P 500 and Dow Reverse Gains as Nasdaq Narrows Upturn
Jan 08 2026
Yahoo Finance
S&P 500 and Dow Retreat from Highs, Eli Lilly and Google Flash Buy Signals
Jan 08 2026
Yahoo Finance
A Biotech Investment Option for Cautious Investors in a Volatile Sector
Dec 09 2025
CNBC
Ligand Pharmaceuticals Introduces 2026 Revenue Guidance of $245M to $285M
Dec 09 2025
Newsfilter
Orchestra BioMed Announces Financial Results for Q3 2025 and Shares Recent Business Developments
Nov 10 2025
Globenewswire
Pelthos Therapeutics Purchases Xepi® (ozenoxacin) Cream, 1%, and Reveals $18 Million Private Convertible Notes Funding
Nov 07 2025
Newsfilter
EXCLUSIVE: Pelthos Acquires Antimicrobial Drug Rights and Raises $18 Million for Commercial Launch Support
Nov 07 2025
Benzinga
HC Wainwright & Co. Reaffirms Buy Rating for Ligand Pharmaceuticals, Increases Price Target to $231
Nov 06 2025
Benzinga
MSTZ and AFSC Experience Significant ETF Withdrawals
Oct 17 2025
NASDAQ.COM
Ligand Scheduled to Hold Investor Day on December 9, 2025
Oct 16 2025
Newsfilter
SQ Innovation, a Ligand Partner, Secures FDA Approval for Lasix® ONYU, a Home Treatment for Edema in Heart Failure Patients
Oct 09 2025
Newsfilter
Ligand Pharmaceuticals Achieves Analyst Price Target
Oct 09 2025
NASDAQ.COM
Arecor Reveals Co-Development Partnership with US Insulin Pump Firm for AT278, Along with Sale of Royalty Rights and Technology Access Fees for AT220 and AT292
Sep 25 2025
Newsfilter
Fidelity MSCI Health Care Index ETF Sees Insider Buying Index at 19.3%
Sep 09 2025
NASDAQ.COM
Oppenheimer Reaffirms Outperform Rating for Ligand Pharmaceuticals and Increases Price Target to $190
Sep 03 2025
Benzinga
Analysts' Insights on Ligand Pharmaceuticals Stock
Sep 02 2025
Benzinga
Show More News
